Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRI assessment of drug-induced fluid accumulation in humans: validation of the technology.
Zuo CS, Villafuerte RA, Henry ME, Dobbins RL, Lee C, Sung Y, Haws C, Butman M, Miller S, Manos A, Orban BS, Brown AP, Hodge R, Nunez DJ, Renshaw PF. Zuo CS, et al. Among authors: dobbins rl. Magn Reson Imaging. 2008 Jun;26(5):629-37. doi: 10.1016/j.mri.2008.01.003. Epub 2008 May 7. Magn Reson Imaging. 2008. PMID: 18420368 Clinical Trial.
Proton and sodium MRI assessment of fluid level in calf tissue.
Zuo CS, Villafuerte RA, Henry ME, Butman M, Dobbins RL, He Y, Orban BS, Cayetano K, Wang L, Brown AP, Nunez DJ, Brown J, Renshaw PF. Zuo CS, et al. Among authors: dobbins rl. J Magn Reson Imaging. 2006 Jul;24(1):191-6. doi: 10.1002/jmri.20624. J Magn Reson Imaging. 2006. PMID: 16758473
Reduced T2* values in soleus muscle of patients with type 2 diabetes mellitus.
Zuo CS, Sung YH, Simonson DC, Habecker E, Wang J, Haws C, Villafuerte RA, Henry ME, Dobbins RL, Hodge RJ, Nunez DJ, Renshaw PF. Zuo CS, et al. Among authors: dobbins rl. PLoS One. 2012;7(11):e49337. doi: 10.1371/journal.pone.0049337. Epub 2012 Nov 26. PLoS One. 2012. PMID: 23189142 Free PMC article.
Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.
Napolitano A, Miller S, Murgatroyd PR, Hussey E, Dobbins RL, Bullmore ET, Nunez DJR. Napolitano A, et al. Among authors: dobbins rl. J Clin Transl Endocrinol. 2013 Dec 11;1(1):e3-e8. doi: 10.1016/j.jcte.2013.12.001. eCollection 2014 Mar. J Clin Transl Endocrinol. 2013. PMID: 29235586 Free PMC article.
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ. Hussey EK, et al. Among authors: dobbins rl. J Clin Pharmacol. 2010 Jun;50(6):636-46. doi: 10.1177/0091270009352185. Epub 2010 Mar 3. J Clin Pharmacol. 2010. PMID: 20200268 Clinical Trial.
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A, O'Connor-Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M, Smith GA, Polli JW, James CD Jr, Mikoshiba I, Nunez DJ. Kapur A, et al. Among authors: dobbins rl. BMC Pharmacol Toxicol. 2013 May 13;14:26. doi: 10.1186/2050-6511-14-26. BMC Pharmacol Toxicol. 2013. PMID: 23668634 Free PMC article. Clinical Trial.
56 results